Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxThe FDA Just Approved a New Sugar Substitute—but is it Healthier?

FDA Approval of Brazzein: A Natural Sweetener’s Potential and Uncertainties

The US Food and Drug Administration (FDA) recently approved brazzein, a natural sweetener derived from the Pentadiplandra brazzeana Baillon fruit, as a zero-calorie alternative to sugar. Although brazzein offers promising benefits for reducing sugar intake, substantial research is still needed to fully understand its effects on human health, especially regarding safety and potential allergenicity. This approval comes as part of an ongoing search for healthier sweetening options amidst rising health concerns linked to sugar and artificial sweeteners.

Key Points:

  • Brazzein Source and Sweetness: Brazzein is a natural protein from a West African plant, approximately 2,000 times sweeter than sucrose, requiring only small quantities for sweetening purposes.
  • FDA Approval and Manufacturer: In March 2024, Oobli became the only US company granted FDA approval to produce brazzein, marking a significant step toward broader availability.
  • Health Implications: Unlike artificial sweeteners, brazzein does not affect blood sugar levels or insulin response, making it potentially safer for diabetic and obese populations.
  • Production Challenges: Due to the difficulty and cost of growing the native plant, production involves fermenting the protein using yeast, bacteria, and transgenic plants, a method needing rigorous safety and efficacy testing.
  • Safety Profile: Currently recognized as generally recognized as safe (GRAS) based on initial research, but further studies are necessary to confirm its long-term safety and effect on different populations, including children and pregnant individuals.
  • Comparative Advantage: Preliminary findings suggest brazzein may avoid the negative effects on the gut microbiome associated with other sweeteners, offering a healthier alternative.
  • Research Needs: There is a call for comprehensive longitudinal studies to better compare brazzein with other natural and artificial sweeteners and to validate its health benefits and safety profile over time.

“The epidemic of diabetes, obesity, and metabolic syndrome requires some sort of solution. This could be a step in the right direction.”
– Nima Majlesi, DO, Director of Medical Toxicology at Staten Island University Hospital

More on Diet & Nutrition

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form